OP107
Anti-BRCA1 (Ab-4) Mouse mAb (SD118)
liquid, clone SD118, Calbiochem®
Synonim(y):
Anti-Breast Cancer Susceptibility Protein
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Kod UNSPSC:
12352203
NACRES:
NA.43
Polecane produkty
pochodzenie biologiczne
mouse
Poziom jakości
forma przeciwciała
purified antibody
rodzaj przeciwciała
primary antibodies
klon
SD118, monoclonal
Postać
liquid
zawiera
≤0.1% sodium azide as preservative
reaktywność gatunkowa
human
producent / nazwa handlowa
Calbiochem®
warunki przechowywania
do not freeze
izotyp
IgG1
Warunki transportu
wet ice
temp. przechowywania
2-8°C
docelowa modyfikacja potranslacyjna
unmodified
informacje o genach
human ... BRCA1(672)
Opis ogólny
Anti-BRCA1 (Ab-4), mouse monoclonal, clone SD118, recognizes the ~220 kDa BRCA1 in HBL-100 and SK-BR3 cells. It is validated for WB, IF, IP, and for frozen sections.
Purified mouse monoclonal antibody generated by immunizing RBF/DnJ mice with the specified immunogen and fusing splenocytes with NS1 mouse myeloma cells (see application references). Recognizes the ~220 kDa BRCA1 protein.
Recognizes the ~220 kDa BRCA1 protein in HBL-100 and SK-BR3 cells. Sold under license of U.S. Patent 5,753,441 and 6,162,897.
Immunogen
Human
a recombinant polypeptide corresponding to amino acids 1005-1313 in exon 11 of human BRCA1
Zastosowanie
Frozen Sections (2 µg/ml)
Immunoblotting (2 µg/ml, see application references)
Immunofluorescence (2 µg/ml)
Immunoprecipitation (2 µg, see application references)
Paraffin Sections (not recommended)
Immunoblotting (2 µg/ml, see application references)
Immunofluorescence (2 µg/ml)
Immunoprecipitation (2 µg, see application references)
Paraffin Sections (not recommended)
Opakowanie
Please refer to vial label for lot-specific concentration.
Ostrzeżenie
Toxicity: Standard Handling (A)
Postać fizyczna
In 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
Komentarz do analizy
Positive Control
HBL-100 or SK-BR3 cells
HBL-100 or SK-BR3 cells
Inne uwagi
Chen, J.J., et al. 1999. Cancer Res.59, 1752s.
Cressman, V.L., et al. 1999. Cell Growth Differ.10, 1.
Irminger-Finger, I., et al. 1999. Biol. Chem.380, 117.
Xu, X., et al. 1999. Nat. Genet.22, 37.
Wilson, C.A., et al. 1999. Nat. Genet.21, 236.
Andres, J.L., et al. 1998. Oncogene16, 2229.
Chen, J., et al. 1998. Mol. Cell2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA95, 5287.
Fan, S., et al. 1998. Int. J. Cancer77, 600.
Gowen, L.C., et al. 1998. Science281, 1009.
Hsu, L.C. and R.L. White. 1998. Proc. Natl. Acad. Sci. USA95, 12983.
Shen, S.X., et al. 1998. Oncogene17, 3115.
Tulchin, N., et al. 1998. Int. J. Oncol.13, 513.
Ludwig, T., et al. 1997. Genes Dev11, 1226.
Ruffner, H. and I.M. Verma. 1997. Proc. Natl. Acad. Sci. USA94, 7138.
Scully, R., et al. 1997. Cell90, 425.
Thakur, S., et al. 1997. Mol. Cell Biol.17, 444.
Wilson, C.A., et al. 1997. Oncogene14, 1.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin Oncol.23, 1.
Chen, Y., et al. 1996. Cancer Res.56, 3168.
Liu, C.Y., et al. 1996. Genes Dev.10, 1835.
Gudas, J.M., et al. 1996. Cell Growth Differ.7, 717.
Scully, R., et al. 1996. Science272, 123.
Vaughn, J.P., et al. 1996. Cell Growth Differ.7, 711.
Wilson, C.A. et al. 1996. Nat. Genet.13, 264.
Thompson, M.E., et al. 1995. Nat. Genet.9, 444.
Miki, Y., et al. 1994. Science266, 66.
Cressman, V.L., et al. 1999. Cell Growth Differ.10, 1.
Irminger-Finger, I., et al. 1999. Biol. Chem.380, 117.
Xu, X., et al. 1999. Nat. Genet.22, 37.
Wilson, C.A., et al. 1999. Nat. Genet.21, 236.
Andres, J.L., et al. 1998. Oncogene16, 2229.
Chen, J., et al. 1998. Mol. Cell2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA95, 5287.
Fan, S., et al. 1998. Int. J. Cancer77, 600.
Gowen, L.C., et al. 1998. Science281, 1009.
Hsu, L.C. and R.L. White. 1998. Proc. Natl. Acad. Sci. USA95, 12983.
Shen, S.X., et al. 1998. Oncogene17, 3115.
Tulchin, N., et al. 1998. Int. J. Oncol.13, 513.
Ludwig, T., et al. 1997. Genes Dev11, 1226.
Ruffner, H. and I.M. Verma. 1997. Proc. Natl. Acad. Sci. USA94, 7138.
Scully, R., et al. 1997. Cell90, 425.
Thakur, S., et al. 1997. Mol. Cell Biol.17, 444.
Wilson, C.A., et al. 1997. Oncogene14, 1.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin Oncol.23, 1.
Chen, Y., et al. 1996. Cancer Res.56, 3168.
Liu, C.Y., et al. 1996. Genes Dev.10, 1835.
Gudas, J.M., et al. 1996. Cell Growth Differ.7, 717.
Scully, R., et al. 1996. Science272, 123.
Vaughn, J.P., et al. 1996. Cell Growth Differ.7, 711.
Wilson, C.A. et al. 1996. Nat. Genet.13, 264.
Thompson, M.E., et al. 1995. Nat. Genet.9, 444.
Miki, Y., et al. 1994. Science266, 66.
Maximal BRCA1 levels are observed in subconfluent cell populations after serum stimulation. Highly specific BRCA1 antibody useful for blotting and IP of full length BRCA1 protein. Antibody should be titrated for optimal results in individual systems.
Informacje prawne
Sold under license of U.S. Patents 5,753,441 and 6,162,897.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
This page may contain text that has been machine translated.
Not finding the right product?
Try our Narzędzie selektora produktów.
Kod klasy składowania
11 - Combustible Solids
Klasa zagrożenia wodnego (WGK)
WGK 1
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Veronica Gomez Godinez et al.
PloS one, 15(4), e0227849-e0227849 (2020-04-29)
Understanding the mitotic DNA damage response (DDR) is critical to our comprehension of cancer, premature aging and developmental disorders which are marked by DNA repair deficiencies. In this study we use a micro-focused laser to induce DNA damage in selected
M Tanikawa et al.
British journal of cancer, 104(8), 1349-1355 (2011-03-17)
The TFII-I is a multifunctional transcriptional factor known to bind specifically to several DNA sequence elements and to mediate growth factor signalling. A microdeletion at the chromosomal location 7q11.23 encoding TFII-I and the related family of transcription factors may result
Myth T S Mok et al.
Traffic (Copenhagen, Denmark), 13(6), 800-814 (2012-03-17)
The breast cancer associated gene 1 (BRCA1)-A protein complex assembles at DNA damage-induced nuclear foci to facilitate repair of double-stranded breaks. Here, we describe the first systematic comparison of the dynamics, copy number and organization of its core components at
Amandine I Garcia et al.
EMBO molecular medicine, 3(5), 279-290 (2011-04-08)
Germ-line mutations in the BRCA1 gene strongly predispose women to breast cancer (lifetime risk up to 80%). Furthermore, the BRCA1 protein is absent or present at very low levels in about one third of sporadic breast cancers. However, the mechanisms
Maria C Villarroel et al.
Molecular cancer therapeutics, 10(1), 3-8 (2010-12-08)
Metastasis and drug resistance are the major causes of mortality in patients with pancreatic cancer. Once developed, the progression of pancreatic cancer metastasis is virtually unstoppable with current therapies. Here, we report the remarkable clinical outcome of a patient with
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej